NAC

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: immunity detox inflammation

Research Overview

Across the abstracts, “NAC” refers to two distinct entities: neoadjuvant chemotherapy (NAC) in oncology and N‑acetylcysteine (NAC) as a pharmacologic/nutritional antioxidant. In oncology, neoadjuvant chemotherapy has been most studied in operable, locally advanced gastrointestinal cancers, with randomized/prospective evidence in colon cancer and resectable pancreatic adenocarcinoma. These studies focus on feasibility, perioperative safety, pathologic response (downstaging/regression), completion of multimodality treatment, and early disease-control endpoints. In contrast, N‑acetylcysteine research spans broad preclinical and clinical domains—oxidative stress/inflammation–related conditions (renal injury/diabetic nephropathy, toxicant/pesticide injury), neurologic and psychiatric disorders, and general “supplement” use—often emphasizing mechanistic pathways (glutathione repletion, NF‑κB cytokine suppression, mitochondrial redox homeostasis and ferroptosis signaling such as SIRT3–SOD2–GPx4).

The strongest evidence in these abstracts supports (1) neoadjuvant chemotherapy as a deliverable and generally safe perioperative strategy in selected operable GI cancers, with demonstrated tumor downstaging and improved early disease-control signals in locally advanced colon cancer, and feasibility/encouraging outcomes for perioperative mFOLFIRINOX in resectable pancreatic cancer (while a FOLFOX strategy showed insufficient efficacy in interim analysis). For N‑acetylcysteine, the most firmly established clinical use remains as an antidote for paracetamol (acetaminophen) poisoning and as a mucolytic, supported by long-standing clinical practice and a well-characterized safety profile. Beyond these indications, the abstracts consistently support biological plausibility (antioxidant/anti-inflammatory effects and glutathione augmentation), and provide strong preclinical/experimental support in settings such as diabetic nephropathy models where NAC attenuates oxidative injury and ferroptosis via defined mitochondrial redox pathways; however, clinical efficacy across many other conditions is described as mixed or limited.

Key areas needing more research include: (1) oncology neoadjuvant chemotherapy—defining which patients benefit most, optimizing regimens and sequencing, and validating biomarkers (e.g., histologic regression) to guide postoperative therapy and long-term outcomes; and (2) N‑acetylcysteine—well-powered, adequately long randomized trials to resolve inconsistent findings across neuropsychiatric, neurodegenerative, and other oxidative-stress–associated conditions, with clearer dose/route standardization and clinically meaningful endpoints. Multiple reviews note that despite widespread use and favorable safety, results in clinical trials can be controversial or incomplete, underscoring the need for rigorous translational studies that connect mechanistic effects (e.g., glutathione restoration, cytokine modulation, ferroptosis pathways) to reproducible patient-level benefit.

1. What conditions has NAC been studied for?

  • Established medical uses: acetaminophen (paracetamol) overdose (antidote) and as a mucolytic (e.g., used in cystic fibrosis protocols).

  • Respiratory diseases (chronic inflammatory/fibrotic): chronic obstructive pulmonary disease (COPD), bronchial asthma, idiopathic pulmonary fibrosis, and silicosis (reviewed as potential/adjunct uses).

  • Kidney disease in diabetes: diabetic nephropathy (DN), including mechanistic work in a large-mammal (beagle) DN model and in renal epithelial cells under high glucose.

  • Neurodegenerative and neurologic conditions: Parkinson’s disease, Alzheimer’s disease, cognitive aging/dementia prevention, neuropathic pain, and stroke (overview paper).

  • Psychiatric disorders: neurodevelopmental disorders (including autism), schizophrenia spectrum disorders (notably negative symptoms), bipolar-related disorders, depressive disorders, anxiety disorders, obsessive-compulsive and related disorders, substance-use disorders, neurocognitive disorders, and chronic pain (psychiatric reviews).

  • Sports/exercise performance: studied as an antioxidant intervention; intravenous NAC has been evaluated for endurance and fatigue.

  • COVID-19: discussed as a potential treatment/prevention candidate based on antioxidant/anti-inflammatory/immune-modulating properties and prior use in critically ill septic patients; mentioned as being used “more recently for COVID-19 patients” (abstract is truncated and does not provide outcomes).

  • Toxicant/pesticide-related injury: reviewed for protection against pesticide-induced oxidative stress across organs.

Important clarification: Several provided abstracts use “NAC” to mean neoadjuvant chemotherapy in cancer (colon and pancreatic cancer). That is unrelated to N-acetylcysteine and is not evidence about the supplement/drug NAC (N-acetylcysteine).

2. Does it work in treating those conditions? Summarize the evidence.

  • Acetaminophen overdose: The abstracts describe NAC as a widely used medicine and an essential-medicines antidote with a well-established safety profile. These statements support established clinical utility, though the provided text does not include trial effect sizes.

  • Mucolytic use / respiratory disease: NAC is described as “widely used because of its mucolytic effects” and part of cystic fibrosis protocols. For other chronic respiratory diseases (COPD, asthma, idiopathic fibrosis, silicosis), the abstract frames benefit as possible and discusses mechanisms (oxidative stress/inflammation) rather than providing definitive RCT outcomes.

  • Diabetic nephropathy: In a 120-day beagle DN model, NAC combined with insulin “further alleviated mitochondrial oxidative damage and ferroptosis” and maintained mitochondrial redox homeostasis; cell work showed NAC reduced high-glucose–induced ferroptosis via Gpx4, with mechanistic reversal using FIN56 (Gpx4 inhibitor) and 3-TYP (implicating the SIRT3-SOD2 axis). This is promising mechanistic/animal evidence, but it is not a human clinical outcomes trial.

  • Psychiatric disorders: Multiple reviews state that clinical trials are mixed and often underpowered and/or too brief; some benefits may appear only after months. One review states NAC has the most evidence as an adjunct for negative symptoms of schizophrenia, severe autism, depression, and obsessive-compulsive and related disorders, but still emphasizes that efficacy is not fully established and better trials are needed.

  • Neurodegenerative disease / cognition / stroke / neuropathic pain: An overview suggests NAC “may be considered helpful” and has been evaluated for neuroprotection and cognitive aging/dementia prevention, but the abstract does not provide definitive clinical trial results; it is suggestive rather than confirmatory.

  • Exercise performance: A sports nutrition review reports that intravenous NAC improved endurance cycling performance and reduced muscle fatigue. The same review cautions that while acute antioxidant intake may be beneficial, chronic intake of most antioxidants has harmful effects on performance (e.g., potentially impairing training adaptations).

  • COVID-19: The abstract proposes NAC as a candidate due to antioxidant/anti-inflammatory/immune-modulating properties and mentions use in septic and COVID-19 patients, but provides no clinical efficacy results in the excerpt provided.

  • Pesticide/toxicant injury: A review describes “growing interest” and suggests protective effects are linked to antioxidant properties (free radical scavenging and glutathione restoration), but this is not presented as definitive clinical efficacy.

Bottom line from these abstracts: Strongest support in the provided text is for established roles (acetaminophen antidote; mucolytic use). For many other conditions, evidence is described as promising but limited, mixed, controversial, incomplete, or mechanistic/preclinical.

3. What health benefits does it have?

  • Antioxidant support via glutathione (GSH): Multiple abstracts emphasize NAC as a glutathione precursor that increases intracellular GSH, supporting redox balance.

  • Anti-inflammatory effects: One abstract states NAC can reduce inflammatory mediators (e.g., TNF-α, IL-6, IL-1β) by suppressing NF-κB activity.

  • Mitochondrial redox/ferroptosis modulation (preclinical): In diabetic nephropathy models, NAC supported mitochondrial redox homeostasis and reduced ferroptosis through a SIRT3–SOD2–Gpx4 signaling pathway (animal/cell evidence).

  • Mucus thinning (mucolytic benefit): Widely used for mucolytic effects, including in cystic fibrosis protocols.

  • Potential neuropsychiatric benefits (adjunctive): Reviews cite plausible mechanisms (oxidative homeostasis, inflammatory mediators, neurotransmitter regulation including glutamate modulation) and note the most consistent signals of benefit as adjunct therapy in certain psychiatric symptom domains (e.g., negative symptoms of schizophrenia; severe autism; depression; OCD-related disorders), though not definitive.

  • Potential exercise benefit (specific context): Intravenous NAC improved endurance cycling performance and reduced fatigue in the reviewed literature, with caution about chronic antioxidant use.

4. Does it have any downsides or side effects?

  • Generally favorable safety profile: One abstract states NAC has a “well-established safety profile,” with toxicity “uncommon” and dependent on route of administration and high dosages.

  • Evidence limitations and inconsistent outcomes: Multiple abstracts emphasize that across many proposed indications, clinical trial results are “limited,” “mixed,” “controversial,” or “incomplete,” meaning potential downsides include uncertain benefit and the risk of using it in place of proven therapies.

  • Sports/training concern: The sports review suggests chronic antioxidant intake (as a class, including NAC by implication in the discussion) may have harmful effects on performance, potentially by impairing training adaptations, whereas acute use may differ.

  • “No relevant side effects observed” claim is context-dependent: One overview states no relevant side effects were observed after administration, but this is a broad statement without dosing/route details in the abstract; other abstracts explicitly note toxicity can occur with high doses and varies by route.

Note: The provided abstracts do not enumerate specific adverse events (e.g., rates of nausea, bronchospasm, anaphylactoid reactions with IV use), so side-effect detail is limited to general safety statements.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (no genotype-stratified outcomes, no specific variants affecting NAC response, dosing, or adverse effects). Mechanistic pathways are discussed (e.g., NF-κB suppression; SIRT3–SOD2–Gpx4 signaling in diabetic nephropathy models), but these are not linked to human genetic variation in the abstracts supplied.

Conclusion based on these abstracts: No evidence here to recommend NAC specifically for, or to avoid it in, particular genetic subgroups.

References

  1. Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial.
    Dion Morton, Matthew Seymour, Laura Magill, Kelly Handley, James Glasbey, Bengt Glimelius, Andy Palmer, Jenny Seligmann, Søren Laurberg, Keigo Murakami, Nick West, Philip Quirke, Richard Gray (2023) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  2. N-Acetylcysteine (NAC): Impacts on Human Health
    Micaely Cristina Dos Santos Tenório, Nayara Gomes Graciliano, Fabiana Andréa Moura, Alane Cabral Menezes de Oliveira, Marília Oliveira Fonseca Goulart (2021)
  3. NAC alleviative ferroptosis in diabetic nephropathy via maintaining mitochondrial redox homeostasis through activating SIRT3-SOD2/Gpx4 pathway.
    Quanwei Li, Jianzhao Liao, Weijin Chen, Kai Zhang, Hongji Li, Feiyang Ma, Hui Zhang, Qingyue Han, Jianying Guo, Ying Li, Lianmei Hu, Jiaqiang Pan, Zhaoxin Tang (2022) - Free radical biology & medicine
  4. A Review on Various Uses of N-Acetyl Cysteine.
    Vida Mokhtari, Parvaneh Afsharian, Maryam Shahhoseini, Seyed Mehdi Kalantar, Ashraf Moini (2017) - Cell journal
  5. Overview on the Effects ofN-Acetylcysteine in Neurodegenerative Diseases
    Giuseppe Tardiolo, Placido Bramanti, Emanuela Mazzon (2018)
  6. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study).
    Lilian Schwarz, Jean-Baptiste Bachet, Aurelia Meurisse, Olivier Bouché, Eric Assenat, Guillaume Piessen, Pascal Hammel, Nicolas Regenet, Julien Taieb, Olivier Turrini, Francois Paye, Anthony Turpin, Francois-Regis Souche, Christophe Laurent, Reza Kianmanesh, Pierre Michel, Dewi Vernerey, Jean-Yves Mabrut, Celia Turco, Stephanie Truant, Antonio Sa Cunha (2025) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  7. Medical and Dietary Uses of N-Acetylcysteine.
    Špela Šalamon, Barbara Kramar, Tinkara Pirc Marolt, Borut Poljšak, Irina Milisav (2019) - Antioxidants (Basel, Switzerland)
  8. A minireview on N-acetylcysteine: An old drug with new approaches.
    Ines Elbini Dhouib, Manel Jallouli, Alya Annabi, Najoua Gharbi, Saloua Elfazaa, Mohamed Montassar Lasram (2016) - Life sciences
  9. The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders.
    Richard C J Bradlow, Michael Berk, Peter W Kalivas, Sudie E Back, Richard A Kanaan (2022) - CNS drugs
  10. Biological Activities and Potential Oral Applications of N-Acetylcysteine: Progress and Prospects.
    Yanping Pei, Huan Liu, Yi Yang, Yanwei Yang, Yang Jiao, Franklin R Tay, Jihua Chen (2018) - Oxidative medicine and cellular longevity
  11. Impact of Dietary Antioxidants on Sport Performance: A Review.
    Andrea J Braakhuis, Will G Hopkins (2015) - Sports medicine (Auckland, N.Z.)
  12. N-acetylcysteine as a new prominent approach for treating psychiatric disorders.
    Irena Smaga, Małgorzata Frankowska, Małgorzata Filip (2021) - British journal of pharmacology
  13. Advances in the Use ofN-Acetylcysteine in Chronic Respiratory Diseases
    Daniela Mokra, Juraj Mokry, Romana Barosova, Juliana Hanusrichterova (2023)
  14. N-Acetylcysteine to Combat COVID-19: An Evidence Review.
    Zhongcheng Shi, Carlos A Puyo (2020) - Therapeutics and clinical risk management
  15. Ferroptosis in Liver Disease: Natural Active Compounds and Therapeutic Implications.
    Zhili Wu, Yanru Zhu, Wenchao Liu, Balamuralikrishnan Balasubramanian, Xiao Xu, Junhu Yao, Xinjian Lei (2024) - Antioxidants (Basel, Switzerland)
  16. GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells.
    Zhen Zhu, Hongyu Shen, Jialin Xu, Zheng Fang, Guanqun Wo, Ying Ma, Kai Yang, Yalin Wang, Qiang Yu, Jin-Hai Tang (2023) - Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  17. Effect of N-Acetylcysteine on Cisplatin Toxicity: A Review of the Literature.
    Angeles Citlali Zavala-Valencia, Liliana Velasco-Hidalgo, Armando Martínez-Avalos, Manuel Castillejos-López, Luz-María Torres-Espíndola (2024) - Biologics : targets & therapy
  18. Cancer-associated fibroblasts undergoing neoadjuvant chemotherapy suppress rectal cancer revealed by single-cell and spatial transcriptomics.
    Pengfei Qin, Huaxian Chen, Yuhang Wang, Liang Huang, Ke Huang, Guozhong Xiao, Changpeng Han, Jiancong Hu, Dezheng Lin, Xingyang Wan, Yihui Zheng, Yufeng Liu, Guiming Li, Haojie Yang, Shubiao Ye, Minyi Luo, Yuanji Fu, Hao Xu, Luping Wen, Zhiwei Guo, Xunan Shen, Zeyu Li, Chunqing Wang, Xi Chen, Linying Wang, Liuyong Sun, Donglin Ren, Liang Wu, Jufang Wang, Shiping Liu, Hongcheng Lin (2023) - Cell reports. Medicine
  19. Drug-Induced Liver Injury: Clinical Evidence of N-Acetyl Cysteine Protective Effects.
    Yonela Ntamo, Khanyisani Ziqubu, Nireshni Chellan, Bongani B Nkambule, Tawanda M Nyambuya, Sithandiwe E Mazibuko-Mbeje, Kwazikwakhe B Gabuza, Fabio Marcheggiani, Luca Tiano, Phiwayinkosi V Dludla (2021) - Oxidative medicine and cellular longevity
  20. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?
    Rossella Reddavid, Silvia Sofia, Paolo Chiaro, Fabio Colli, Renza Trapani, Laura Esposito, Mario Solej, Maurizio Degiuli (2018) - World journal of gastroenterology


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!